ITEN to Launch the Industrial-Scale Production of Its All-Solid-State Battery Powency Product Family
8.11.2024 09:00:00 CET | Business Wire | Press release
Electronica 2024 Trade Fair--ITEN, a pioneer in the development and production of solid-state batteries for electronics markets, today announced the production launch of its new Powency family of rechargeable Li-ion batteries. The new family consists of high-power density batteries, including for now the PWY0150S battery, available in pre-production, and the PWY0250S battery, available as engineering samples. Those first Powency batteries respectively have a capacity of 150µAh and 250µAh. The Powency product family, which is manufactured at the ITEN facility in France, is a testament to the demonstration of ITEN's technological and industrial leadership in the field of solid-state batteries.
ITEN will participate in the Electronica trade show in Munich from November 12 to 15, 2024 (Hall B4 - Stand E05) to showcase both PWY0150S and PWY0250S.
Powency PWY0150S and PWY0250S, solid-state energy storage in an unmatched form factor
The Powency PWS0150S and PWS0250S batteries are designed to deliver energy peaks to connected devices or to power electronic systems during a power outage. Both products feature a high-power density in an ultra-compact design, measuring 25mm³ and weighing 73 milligrams; they can supply the current levels required by connected devices operating with LAN wireless protocols. The Powency PWS0150S and PWS0250S are available as SMD devices, enabling an easy integration with automated production lines. Powency PWS0150S and PWS0250S are based on ITENS' all-solid-state battery technologies, contain no heavy metals, toxic chemicals or organic solvents, and can be recycled as passive electronic components.
Powency PWY0150S and PWY0250S, designed to address the energy efficiency challenges for the IoT and maintenance-free wireless sensors
Powering low-power, small-form-factor devices is a major obstacle in the emergence and broad implementation of the Internet of Things (IoT). The Powency products will enable IoT device makers to build high-performance Bluetooth Low Energy (BLE), 802.15.4, or NFC systems in an unrivaled form factor. They facilitate the widespread use of maintenance-free devices that harvest energy from external sources such as indoor or outdoor ambient light, ambient radio waves, and / or kinetic motion. PWY0150S is currently being manufactured in pre-series for numerous early-stage customers and serves as the ideal energy reservoir in autonomous sensors that are powered by Energy Harvesting.
Powency PWY0150S and PWY0250S, "Sustainability by design, process, and function"
The Powency product family, like all ITEN-developed products, is designed and manufactured to minimize its environmental impact and adhere to the company’s motto "sustainability by design, by process and by function." ITEN batteries are composed of ceramic, and are free of organic materials and critical metals like cobalt. They are rechargeable and completely recyclable.
Vincent Cobée, CEO of ITEN, said: "Our presence at the Electronica Trade Show, this essential event in the electronics industry, is very important for ITEN, at a key moment in the company’s growth. The commercial introduction and mass production of the Powency product family have indeed marked a significant milestone in the company's evolution. We were able to develop solutions that the market expected, in terms of both product and integration into our clients' various industrial processes, to provide a sustainable, high-performance, and genuinely integrated response. The trajectory will be further accelerated in the upcoming months by the introduction of a new battery that is even more potent, as well as the offering of two distinct solutions.”
More information available on www.iten.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101283870/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom